Disorders of the Nervous System

Acute Nicotine Exposure Alters Ventral Tegmental Area Inhibitory Transmission and Promotes Diazepam Consumption

Alexey Ostroumov, Ruthie E. Wittenberg, Blake A. Kimmey, Madison B. Taormina, William M. Holden, Albert T. McHugh, and John A. Dani

https://doi.org/10.1523/ENEURO.0348-19.2020

Department of Neuroscience, Mahoney Institute for Neurosciences, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104

Abstract

Nicotine use increases the risk for subsequent abuse of other addictive drugs, but the biological basis underlying this risk remains largely unknown. Interactions between nicotine and other drugs of abuse may arise from nicotine-induced neural adaptations in the mesolimbic dopamine (DA) system, a common pathway for the reinforcing effects of many addictive substances. Previous work identified nicotine-induced neuroadaptations that alter inhibitory transmission in the ventral tegmental area (VTA). Here, we test whether nicotine-induced dysregulation of GABAergic signaling within the VTA increases the vulnerability for benzodiazepine abuse that has been reported in smokers. We demonstrate in rats that nicotine exposure dysregulates diazepam-induced inhibition of VTA GABA neurons and increases diazepam consumption. In VTA GABA neurons, nicotine impaired KCC2-mediated chloride extrusion, depolarized the GABA$\text{A}$ reversal potential, and shifted the pharmacological effect of diazepam on GABA neurons from inhibition toward excitation. In parallel, nicotine-related alterations in GABA$\text{A}$ function observed ex vivo were associated with enhanced diazepam-induced inhibition of lateral VTA DA neurons in vivo. Targeting KCC2 with the agonist CLP290 normalized diazepam-induced effects on VTA GABA$\text{A}$ transmission and reduced diazepam consumption following nicotine administration to the control level. Together, our results provide insights into midbrain circuit alterations resulting from nicotine exposure that contribute to the abuse of other drugs, such as benzodiazepines.

Key words: benzodiazepines; chloride; dopamine; GABA; KCC2; mesolimbic

Significance Statement

Benzodiazepines, particularly diazepam, are among the most frequently prescribed drugs for their anxiolytic, sedative, and anti-convulsant effects. In general, benzodiazepines have a relatively low abuse liability, yet misuse occurs more frequently among smokers. Pharmacologically, benzodiazepines act on the GABA$\text{A}$ receptor (GABA$\text{A}_{\text{R}}$), enhancing the effect of the inhibitory neurotransmitter. Our work suggests that nicotine increases vulnerability to diazepam use via aberrant inhibitory signaling in the ventral tegmental area (VTA), a principle nucleus of the brain’s reward system. Specifically, we found that nicotine exposure impaired VTA GABA$\text{A}_{\text{R}}$ function, resulting in altered effects of diazepam on dopamine (DA) circuitry and increased diazepam consumption. Furthermore, we identify a novel therapeutic target, which may serve to mitigate excessive diazepam consumption in smoking or vaping individuals.
Introduction

Nicotine is the main addictive component of tobacco and electronic cigarettes. Epidemiological and animal studies indicate that, along with other harmful effects, nicotine use positively correlates with the intake of other addictive drugs, acting as a gateway for subsequent substance abuse (Kandel, 1975; Boscario et al., 2010; Huizink et al., 2010; Harrison and McKee, 2011; Levine et al., 2011; Mello and Newman, 2011; Doyon et al., 2013; Kandel and Kandel, 2014; Miech et al., 2016; Thomas et al., 2018). The specific mechanisms by which nicotine increases vulnerability for subsequent addiction to other substances are not fully understood, but likely involve nicotine-induced adaptations in the reward system of the brain. Accumulating evidence indicates that chronic nicotine exposure dysregulates GABAergic signaling in the ventral tegmental area (VTA), a key dopaminergic brain area involved in the rewarding properties of virtually all addictive drugs (Vihavainen et al., 2008b; Li et al., 2014; Bucznyski et al., 2016; Thomas et al., 2018). To date, nicotine-induced changes in VTA GABAergic transmission have been shown to influence dopamine (DA) signaling and behavioral responses to alcohol and morphine (Vihavainen et al., 2008a,b; Thomas et al., 2018). We postulate that, in addition to these drugs, nicotine-induced neuroadaptation of VTA inhibitory transmission can modify the action of addictive substances that specifically target GABA_A receptors (GABA_ARs).

Among the different classes of GABA_A-R-targeting drugs, benzodiazepine misuse is a growing public health problem in the United States, with prescription rates and overdose mortality spiking in recent years (Bachhuber et al., 2016; Lembke et al., 2018; Maust et al., 2019). Acting through positive allosteric modulation of GABA_ARs, benzodiazepines are regularly prescribed for panic attacks, insomnia, and seizures. Unfortunately, these drugs also retain a liability for abuse and dependence, especially in polydrug users and individuals with comorbid anxiety and depression (Woods et al., 1992; Griffiths and Weerts, 1997; Licata and Rowlett, 2008). Interestingly, benzodiazepine abuse is more likely to occur in smokers (Dunbar et al., 1988; Lekka et al., 1997; Neutel, 2005), and evidence from rodents shows that exposure to nicotine increases the reinforcing properties of benzodiazepines (White, 1989; Irvine et al., 2001; James-Walke et al., 2007). Like nicotine, benzodiazepine reinforcement involves midbrain GABAergic signaling, as genetic manipulation of GABA_ARs in the VTA was shown to decrease benzodiazepine consumption (Tan et al., 2010; Tolu et al., 2013). In contrast to DA neurons, VTA GABA neurons are particularly sensitive to benzodiazepines, demonstrating drug-mediated inhibition of neuronal firing (O’Brien and White, 1987; Tan et al., 2010). For these reasons, VTA GABA neurons may represent a critical locus of interaction for the association between nicotine exposure and subsequent benzodiazepine abuse.

To examine basic neural mechanisms linking nicotine to benzodiazepine abuse, we studied how nicotine exposure in naive rats alters subsequent responses to the benzodiazepine diazepam, including diazepam-induced VTA neuron signaling and diazepam intake. Given that GABA_A-R signaling in VTA GABA neurons is impacted by chronic nicotine exposure (Thomas et al., 2018), we hypothesized that similar nicotine-induced neuroadaptations modify diazepam action on midbrain circuitry. Indeed, we found that a single, non-contingent nicotine exposure and volitional consumption of nicotine both dysregulate GABA_A-R signaling within VTA GABA neurons via downregulation of the K⁺, Cl⁻ co-transporter KCC2. This impaired Cl⁻ homeostasis and shifted diazepam-induced inhibition of VTA GABA neurons towards paradoxical excitation, which was associated with decreased DA neuron firing in response to diazepam. At the behavioral level, a single exposure to nicotine increased diazepam consumption, an effect that could be reversed by enhancing KCC2 function. These results indicate that nicotine exposure fundamentally alters the effects of diazepam on mesolimbic DA circuitry and thereby contributes to increased diazepam intake.

Materials and Methods

Animals

Male Long–Evans rats (Harlan-Envigo, weighing 300–500 g) were housed in a quiet, temperature-controlled and humidity-controlled facility under a 12/12 h light/dark cycle. Rats had food and water available ad libitum in their home cages. All rats were group housed except for use in behavior experiments when animals were transitioned to single-housing at the onset of daily drinking. All rats were handled at least 5 d prior to the beginning of testing. All animal procedures were performed in accordance with the University of Pennsylvania animal care committee’s regulations.

Drugs and experimental design

Systemic administration of nicotine (0.4 mg/kg, free-base, i.p., Glenthom Life Sciences) or saline (0.9% saline, i.p., Hospira) occurred 7–15 h prior to diazepam exposure or testing. For systemic administration, CLP290 was first dissolved in 40% β-cyclodextrin (20 mg/ml), then diluted...
in saline to a final concentration of 10 mg/ml in 20% β-cyclo-dextrin (Gagnon et al., 2013). Using 10 N NaOH, the pH was adjusted to be between 5 and 6. Systemic administration of CLP290 (10 mg/kg, i.p.) or vehicle (20% β-cyclo-dextrin) occurred 45 min prior to diazepam intake sessions over three non-consecutive days (Thomas et al., 2018). In ex vivo experiments, slices were incubated for 1 h in 10 μM CLP290, which was first dissolved in DMSO (100 mM), then diluted in artificial CSF (ACSF) to a final concentration. The carbonic anhydrase inhibitor acetazolamide (ACTZ) was bath applied at concentration of 10 μM. Diazepam (Sigma Aldrich) was dissolved in 190 proof ethanol before it was dissolved daily in the saccharin drinking solution. The final concentration of ethanol in the solution was 0.0475%. Drugs used for electrophysiologically recordings were obtained from Sigma Aldrich unless otherwise specified. CLP290 was a generous gift from Dr. Y. De Koninck and Dr. A. Castonguay (Laval University, Quebec, Canada).

**Ex vivo electrophysiology**

Horizontal slices (230 μm) containing the VTA were cut (Leica Microsystems) from adult and juvenile (P21–P28) Long–Evans rats in ice-cold, oxygenated (95% O2, 5% CO2), high-sucrose ACSF: 205.0 mM sucrose, 2.5 mM KCl, 21.4 mM NaHCO3, 1.2 mM NaH2PO4, 0.5 mM CaCl2, 7.5 mM MgCl2, and 11.1 mM dextrose. Immediately after cutting, slices were transferred to normal ACSF buffer: 120.0 mM NaCl, 3.3 mM KCl, 25.0 mM NaHCO3, 1.2 mM NaH2PO4, 2.0 mM CaCl2, 1.0 mM MgCl2, 10.0 mM dextrose, and 20.0 mM sucrose. The slices were constantly oxygenated (95% O2, 5%CO2) and maintained at 32°C in ACSF for 40 min, then at room temperature for at least 60 min. For incubation experiments, slices were bathed in CLP290 (10 μM) for an additional hour prior to recording. To perform electrophysiological recordings, slices were transferred to a holding chamber and perfused with normal ACSF at a constant rate of 2–3 ml/min at 32°C. Patch electrodes made of thin-walled borosilicate glass [1.12 mm inner diameter (ID), 1.5 mm outer diameter (OD); World Precision Instruments (WPI)] had resistances of 1.0–2.0 MΩ when filled with the internal solution: 135.0 mM KCl, 12.0 mM NaCl, 2.0 mM Mg-ATP, 0.5 mM EGTA, 10.0 mM HEPES, and 0.3 mM Tris-GTP (pH 7.2–7.3). For E_GABA perforated-patch recordings in VTA GABA neurons, gramicidin was first dissolved in methanol to a concentration of 10 mg/ml and then diluted in a pipette solution to a final concentration of 150 μg/ml. For synaptic stimulation recordings, a bipolar tungsten-stimulating electrode (World Precision Instruments) was placed 100–150 μm away from the recording electrode. To determine E_GABA, evoked IPSCs (eIPSCs) were measured under voltage-clamp at different holding potentials. Amplitudes of eIPSCs were plotted against voltage to estimate the reversal potential. After each perforated-patch experiment, recordings were converted to the whole-cell configuration, and the hyperpolarization-activated current (i_h) was measured. Recordings were performed in the presence of 6,7-dinitroquinoxaline-2,3-dione (DNQX; 20 μM) and DL-2-amino-5-phosphonopentanoic acid (AP5, 50 μM; Tocris Bioscience), CGP55845 (1 μM), and tetrodotoxin (0.5 μM, Abcam) to isolate GABAergic currents.

Analogous experiments were conducted to determine whether acute nicotine altered E_GABA in young rats (P21–P28). Indistinguishable from adult animals, VTA GABA neurons from P21 to P28 rats receiving nicotine showed a significantly more depolarized E_GABA value compared with saline-treated controls: −63.8 ± 4.3 mV after nicotine, −87.6 ± 2.4 mV after saline, n = 7, n = 8 cells/group, n = 4, n = 5 rats/group, t = 4.956, p = 0.000 (Table 1, line a). Cell visualization and long-term patch-clamp recordings in slices from adult rats are harder compared with juvenile rats. Therefore, given the similarity of nicotine effects between young and adult rats, subsequent ex vivo electrophysiological recordings were performed in midbrain slices from juvenile rats.

To measure activity-dependent depression of eIPSCs, whole-cell recordings were performed during repetitive stimulation. The estimated GABA reversal was approximately −70 mV, and the internal solution contained the following: 123.0 mM K+–glucuronate, 8.0 mM NaCl, 2.0 mM Mg-ATP, 0.2 mM EGTA, 10.0 mM HEPES, and 0.3 mM Tris-GTP (pH 7.2–7.3). Synaptic GABA_A input was isolated using DNQX, AP5, and CGP55845. The liquid junction potential between the bath and the pipette solutions was corrected.

The effects of diazepam on firing rates of VTA GABA neurons were recorded in cell-attached configuration in passive voltage-follower mode. For focal puff application of diazepam, the puff capillary was placed 10–20 μm from the patched neuron. Brief (150–300 ms) focal pressure ejections (one to three puffs at 1.3 Hz) of diazepam (0.5 mM) occurred at 1 min intervals following recording of baseline firing. After each cell-attached experiment, recordings were converted to the whole-cell configuration and i_h was measured. Some cells were also backfilled with neurobiotin for immuno-identification. Spontaneous IPSCs (sIPSCs) onto VTA DA neurons were recorded in voltage-clamp mode in whole-cell configuration. Synaptic GABA_A inputs were isolated pharmacologically with the AMPA and NMDA-type glutamate receptor antagonists DNQX and AP5. Additional sIPSC experiments were also performed with ACTZ (10 μM) in the bath or CLP incubation (10 μM).

All electrophysiological recordings were performed in the lateral VTA (Fig. 1A). VTA GABA neurons were identified by a combination of factors, including small somata size, high firing rate (>7 Hz), and the lack of i_h (Fig. 1B). Cells with these properties were consistently tyrosine hydroxylase (TH) negative (>95%, Fig. 1C; Klink et al., 2001; Korotkova et al., 2006; Margolis et al., 2006; Ostroumov et al., 2016). Alternatively, DA neurons were identified in the lateral VTA by their morphology (>20-μm soma size), their low firing frequency (<5 Hz), and the presence of a large i_h (Fig. 1D,E). Together, these criteria are shown to correlate with TH-positive cells using immunocytochemistry approaches (95%: Fig. 1F; Chen et al., 2008; Zhang et al., 2010; Ostroumov et al., 2016).

Recordings were made using an Axopatch 200B amplifier (Molecular Devices), filtered at 10 kHz, digitized at 20 kHz using pClamp 9.2 (Digidata Interface, Molecular Devices), and analyzed off-line using Clampfit 9.2.
Western blotting

The VTA was harvested in horizontal brain slices from adult rats and prepared as described previously (see above, Ex vivo electrophysiology). Membrane fractions were prepared using the Mem-PER Plus Membrane Protein Extraction kit (model 89842; Thermo Scientific). Samples (30–50 μg protein) in 2.5% 2-mercaptoethanol were run through a 4%–15% Precast Protein Gel (#4561083; Bio-Rad) and transferred to nitrocellulose membrane (Bio-Rad). The primary antibodies used were rabbit anti-KCC2 antibody at 1:400 (#07-432; Millipore) and mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (#MAB374; Millipore) at 1:400. The secondary antibodies used were goat anti-rabbit immunoglobulin (Ig) G secondary antibody (#T2191; Applied Biosystems) or goat anti-mouse IgG/IgM (#T2192, Applied Biosystems). All antibodies were diluted in SignalBoost solution (#407207; EMD Millipore). Membranes were developed using Tropix CDP-Star solution (T2218; Applied Biosystems) for 5 min and then scanned using the Protein Simple FluorChem R chemiluminescence detector and analyzed using ImageJ. The optical densities of KCC2-specific bands were measured and normalized to the loading control GAPDH values.

In vivo electrophysiology

Rats were anesthetized with isoflurane and implanted with a catheter in the jugular vein. Animals were positioned on a stereotaxic apparatus and an incision in the middle was made to expose the skull. Burr holes were drilled to accommodate recording and ground electrodes. Rat body temperature was maintained throughout the experiment at 37°C using an isothermal pad (Braintree Scientific).

Electrodes were pulled on a horizontal puller (Sutter Instrument) from filament-containing borosilicate glass (0.68 mm ID, 1.2 mm OD; WPI). Electrodes were backfilled with 0.5 M Na+ acetate and 2% Chicago sky blue (5–15 M). Electrodes were slowly lowered with a micromanipulator and positioned in the lateral VTA (coordinates 5.3–6.0 mm posterior from bregma, 0.8–1.4 mm lateral to midline and 7.5–8.5 mm ventral to brain surface). Electrical signals were recorded using an AM Systems Model 1700 amplifier, filtered at 0.3–5 kHz and monitored using pClamp 8.0 (Molecular Devices) and an audiomonitor (Grass Instruments).

Lateral VTA DA neurons were identified based on their electrophysiological and pharmacological properties. Putative DA neurons exhibited low-frequency spontaneous firing (<10 Hz, irregular or bursting) and a broad action potential waveform (>3 ms; Fig. 1G). In addition to electrophysiological criteria, we used pharmacological methods to identify DA neurons. DA neurons included in this study decreased their firing in response to D2 receptor agonist (quinpirole, 0.25 mg/kg, i.v.), and this effect was reversed by application of D2 receptor antagonist (eticlopride, 0.25 mg/kg, i.v.; Fig. 1H). This combination of conservative electrophysiological and pharmacological criteria is a reliable methodology to identify DA neurons in the lateral VTA (Ungless and Grace, 2012).

Table 1. Statistical table

| Data structure | Type of test                      | p value       | Effect size | Power |
|---------------|----------------------------------|---------------|-------------|-------|
| a Normal      | t test                           | 0.000         | 3.438       | 1.000 |
| b Normal      | t test                           | 7.039 \times 10^{-5} | 3.362       | 1.000 |
| c Normal      | t test                           | 0.245         | 0.582       | 0.307 |
| d Normal      | ANOVA repeated measures          | 0.736         | 0.022       | 0.164 |
| e Normal      | ANOVA repeated measures          | 0.000         | 0.357       | 1.000 |
| f Normal      | Pairing t test                   | 0.006         | 1.848       | 0.946 |
| g Normal      | Pairing t test                   | 0.033         | 1.196       | 0.652 |
| h Normal      | t test                           | 0.000         | 3.430       | 1.000 |
| i Normal      | Pairing t test                   | 0.047         | 1.069       | 0.559 |
| j Normal      | Pairing t test                   | 0.049         | 1.056       | 0.549 |
| k Normal      | t test                           | 0.137         | 0.816       | 0.440 |
| l Normal      | ANOVA repeated measures          | 0.000         | 0.449       | 1.000 |
| m Normal      | t test                           | 0.001         | 1.232       | 0.936 |
| n Normal      | t test                           | 0.817         | 0.085       | 0.056 |
| o Normal      | t test                           | 0.965         | 0.016       | 0.050 |
| p Normal      | t test                           | 0.000         | 3.869       | 1.000 |
| q Normal      | t test                           | 0.674         | 0.123       | 0.062 |
| r Normal      | t test                           | 0.491         | 0.379       | 0.100 |
| s Normal      | t test                           | 0.232         | 0.826       | 0.315 |
| t Normal      | t test                           | 0.926         | 0.133       | 0.056 |
| u Normal      | t test                           | 0.001         | 2.202       | 0.965 |
| v Normal      | ANOVA repeated measures          | 0.000         | 0.265       | 1.000 |
| w Normal      | ANOVA repeated measures          | 0.029         | 0.252       | 0.616 |
| x Normal      | t test                           | 0.029         | 1.617       | 0.912 |
| y Normal      | ANOVA repeated measures          | 0.940         | 0.000       | 0.051 |
| z Normal      | t test                           | 0.940         | 0.034       | 0.051 |
| aa Normal     | ANOVA repeated measures          | 0.040         | 0.165       | 0.551 |
| bb Normal     | t test                           | 0.040         | 0.802       | 0.491 |

Effect sizes and power were calculated with G-Power 3.1.
After 6–20 min of stable neuronal recording (basal activity), a 0.25 mg/kg dose of diazepam was injected intravenously. Only one cell was recorded per rat. Drug-induced modifications of the basal activity were calculated in percentage for the 3- to 7-min period following each administration of diazepam and compared with the predrug baseline. Following diazepam administration, quinpirole and eticlopride were injected intravenously for pharmacological identification of VTA neurons. After recording, the cell location was labeled by application of Chicago sky blue dye. The dye was injected via administering positive pressure (1–2 min) through the suction port in the microelectrode holder. At the end of experiment, brains were kept in 10% formalin for at least 1 d. The brains were cut into 75-μm coronal sections on a vibratome (Leica Microsystems Inc.) and stained with cresyl violet to verify the recording site by light microscopy.

Limited access nicotine consumption
Initially, rats received 1-h access to saccharin solution (0.125%) in a chamber distinct from their home cage. Baseline saccharin consumption was monitored for at least 5 d until intake appeared stable. Nicotine was then introduced into the saccharin drinking solution in the following way: 0.004 mg/ml nicotine (freebase) on day 1 and 0.008 mg/ml nicotine (freebase) for the subsequent 6 d. The control group was never introduced to nicotine and received saccharin control solution for the same number of sessions. Similar to the baseline days, rats also had 1-h access to these nicotine or saccharin solutions for the 7 d. Western blotting or electrophysiological measurements were performed the day after the last nicotine or saccharin session.

Limited access diazepam consumption
All rats were handled and habituated to injections for 5 d prior to the start of experiments. Each day at the onset of the dark cycle (7 P.M.), water bottles were replaced with bottles containing 0.125% saccharin dissolved in water. Solution intake was measured 2 h later by subtracting the weight of the bottles at 9 P.M. from the initial weight of the bottles before placement in the cages at 7 P.M. An empty control cage was used to account for any leakage from the experimental bottles. Saccharin drinking proceeded for 7–10 d until the stable baseline drinking...
levels were achieved (defined as ±1 SD of the last three saccharin days for each rat).

The day following the final baseline session of saccharin drinking, rats were injected with either nicotine or saline, intraperitoneally, 7 h prior to drinking. Diazepam was then introduced into the drinking solution that night at 7 P.M. Diazepam was dissolved to a concentration of 0.005 mg/ml in the saccharin drinking solution. Doses of diazepam achieved were expressed as mg/kg. Rats whose baseline saccharin drinking prior to diazepam exposure fell outside of our acceptable range of saccharin consumption, defined as 2 SD above and below the mean baseline saccharin consumption of all rats (14.1 g), did not receive diazepam or proceed with the experiment. This was done in order to ensure that rats were consuming enough solution to achieve a pharmacologically relevant dose of diazepam.

Statistical analyses

A two-tailed t test was used to assess differences between the mean GABA reversal potential, sIPSC frequency, and DA neuron firing rate. For Western blot analysis, a paired t test was used to compare protein levels from saline-treated and nicotine-treated littermates that were run on the same gel. ANOVA with repeated measures was used to analyze the repetitive synaptic stimulation experiment, action potential firing in VTA GABA neurons, and daily diazepam intake. For analysis of action potential firing, the raw data were converted into percent of basal, and the last three bins (2 min each) before bath application of diazepam were used as the baseline. Significance for all analyses was determined by p < 0.05. All statistical analysis was performed using SPSS software (IBM Corp.).

Results

Nicotine impairs Cl− homeostasis in VTA GABA neurons

A recent study that repeated nicotine exposure during adolescence modifies inhibitory synaptic transmission in the VTA via depolarizing shifts in the GABAAR reversal potential (E_{GABA}) of GABA neurons (Thomas et al., 2018). To determine whether acute nicotine exposure was sufficient to alter E_{GABA}, rats were treated with nicotine (0.4 mg/kg) or saline 15 h prior to electrophysiological recordings from midbrain slices. We chose the 15-h pre-treatment period to examine the lasting impact of nicotine on neural circuits, and not the immediate pharmacological effect of nicotine itself. We measured GABAAR currents at different membrane potentials following electrical stimulation (Fig. 2A,B). VTA GABA neurons from rats receiving nicotine showed a significantly more depolarized E_{GABA} value compared with saline-treated controls (Fig. 2B,C): −62.3 ± 2.5 mV after nicotine (red data) versus −65.5 ± 1.9 mV after saline (black data), n = 13, n = 14 cells/group, n = 7 rats/group, t = 7.252, p = 7.039 × 10^{-8} (Table 1, line b). Although E_{GABA} was depolarized, acute nicotine did not alter the membrane resting potential (measured as zero holding current): −62.7 ± 2.7 mV after nicotine, −58.8 ± 1.8 mV after saline, n = 13, n = 14 cells/group, n = 7 rats/group, t = −1.191, p = 0.245 (Table 1, line c). A depolarizing shift in E_{GABA} reflects a higher intracellular anion concentration and is often mediated by a decrease in Cl− extrusion capacity. During prolonged GABAAR stimulation, decreased Cl− extrusion capacity leads to intracellular Cl− accumulation, culminating in the collapse of the Cl− gradient and decreased synaptic GABAAR inhibition. To test whether acute nicotine administration weakens Cl− extrusion in VTA GABA neurons, we established a similar Cl− gradient in cells from nicotine and saline-treated rats by using the whole-cell patch clamp recording configuration. Then, we applied repetitive GABAAR stimulation to measure activity-dependent collapse of the Cl− gradient, which is reflected in the depression of the eIPSCs (Hewitt et al., 2009; Ostrovoum et al., 2016; Ferrini et al., 2017). Specifically, the rate of decrease of eIPSC amplitude at the conditions that favor Cl− influx (0 mV) depends on intracellular Cl− accumulation and activity-dependent synaptic depression. In contrast, the rate of eIPSC amplitude decrease at the conditions of Cl− efflux (~90 mV) only reflect activity-dependent synaptic depression. Upon electrical stimulation at 20 Hz at a holding potential of ~90 mV, nicotine did not affect the rate of synaptic depression in VTA GABA neurons (Fig. 2D): group × number, F_{(4,88)} = 0.499, p = 0.736 (Table 1, line d). In contrast, the decrease in eIPSC amplitude at 0 mV occurred significantly faster after nicotine pretreatment (Fig. 2E): group × number, F_{(4,88)} = 12.240, p = 0.000 (Table 1, line e). The differential effect of acute nicotine at ~90 versus 0 mV indicates that nicotine increased postsynaptic Cl− accumulation, suggesting a reduced capacity for Cl− extrusion in VTA GABA neurons.

Reductions in Cl− extrusion capacity in neurons are often mediated by the downregulation of KCC2 (Ostrovoum et al., 2016; Thomas et al., 2018). Within the VTA, KCC2 protein is expressed on non-DA, GABAergic neurons, which is consistent with the presence of another chloride extrusion mechanism in DA neurons (Gulacsi et al., 2003; Ostrovoum et al., 2016; Taylor et al., 2016; Thomas et al., 2018). To examine acute nicotine-induced alterations in KCC2 protein expression, we performed Western blot analysis using an antibody against KCC2 protein. Immunoblots revealed two prominent bands (~140 and ~270 kDa), indicating the presence of monomeric and dimeric structures of KCC2 protein (Fig. 2F). A significant reduction in the expression of KCC2 was observed after acute nicotine pretreatment (Fig. 2G): 59.9 ± 7.0% for monomer, 59.0 ± 10.6% for dimer, n = 6 rats/group, t = 4.526, p = 0.006 for monomer (Table 1, line f), t = 2.930, p = 0.033 for dimer (Table 1, line g). Our results indicate that acute nicotine decreases KCC2 expression and function, leading to impaired Cl− homeostasis in VTA GABA neurons.

In addition to acute noncontingent nicotine exposure (i.e., experimenter-administered), we measured chloride homeostasis in rats that received 1-h daily access to nicotine in saccharin drinking solution. Under this paradigm, rats demonstrated stable intake of nicotine (0.15 ± 0.01 mg/kg, n = 11 rats; Fig. 3A,B). Seven nicotine drinking sessions led to a significantly depolarized E_{GABA} value in
Figure 2. Acute nicotine exposure alters Cl⁻ homeostasis in the VTA. A, GABAergic input onto VTA GABA neurons was measured using gramicidin perforated-patch whole-cell recordings at different holding potentials to measure nicotine-induced alterations in anion homeostasis. GABA_A IPSCs were evoked by electrical stimulation in the presence of ionotropic glutamate and GABA_B receptor antagonists. B, Representative eIPSC recordings from saline (black) and nicotine (red)-treated animals at the given holding potentials (V_h). The eIPSCs reverse direction at E_GABA. For display, the traces were filtered, and stimulus artifacts were removed. C, VTA GABA neurons from nicotine-treated animals (red) showed a significantly more positive E_GABA compared with saline-treated animals (black); *p < 0.01, significantly different by t test, n = 13, n = 14 cells/group, n = 7 rats/group. D, Activity-dependent synaptic depression in VTA GABA neurons was measured during whole-cell patch clamp recordings under repetitive GABA_A stimulation. Traces on top: representative GABA neurons from saline (black) and nicotine-treated rats (red) demonstrated a similar depression in eIPSC amplitude when stimulated at 20 Hz and clamped at -90 mV. Bottom graph, At -90 mV, VTA GABA neurons from control and stressed animals showed no significant difference in rate of eIPSC amplitude depression (p > 0.05, n = 8 cells, n = 4 rats for the nicotine group and n = 16 cells, n = 6 rats for the saline group). Amplitude values were averaged for five eIPSCs and shown as a percent of the first five eIPSCs mean amplitude. E, Cl⁻ accumulation was measured as in D, but VTA GABA neurons were clamped at 0 mV. Top traces, Upon stimulation, VTA GABA neuron from control animal (black) demonstrated a minor depression of eIPSC amplitude compared with the significantly greater depression seen in a GABA neuron from a stressed animal (red). Bottom graph, At 0 mV, GABA neurons from nicotine treated animals (red) demonstrated a significantly greater rate of eIPSC amplitude depression than GABA neurons from saline-treated animals (black); *p < 0.01, significantly different by ANOVA with repeated measures, n = 8 cells, n = 4 rats for the nicotine group and n = 16 cells, n = 6 rats for the saline group. F, Western blot analysis was conducted for KCC2 protein expression with GAPDH as a loading control. A representative Western blotting shows reduced expression of KCC2.
in nicotine-treated animals. G. Densiometric analysis showed a significant reduction in KCC2 protein in nicotine-treated animals (red bars) compared with saline-treated controls (horizontal dashed line); *p < 0.05, **p < 0.01, significantly different by paired t test, n = 6 animals/group.

VTA GABA neurons compared with seven drinking sessions of saccharin alone (Fig. 3C): –59.5 ± 3.3 mV after nicotine (red data) versus –82.0 ± 2.3 mV in saccharin controls (black data), n = 6, n = 8 cells/group, n = 3 rats/group, t = 5.724, p = 9.544 × 10⁻⁵ (Table 1, line h). In addition, we observed a significant reduction in KCC2 expression within the VTA after 7 d of nicotine consumption (Fig. 3D): 65.0 ± 11.3% for monomer, t = 2.618, p = 0.047; 66.6 ± 9.5% for dimer, t = 2.587, p = 0.049, n = 6 rats/group (Table 1, lines i, j). Taken together, these data indicate that different methods of nicotine administration induce similar alterations in KCC2 expression, chloride homeostasis, and GABAAergic signaling within VTA GABA neurons.

Acute nicotine exposure shifts the effect of diazepam in VTA GABA neurons
Depolarizing shifts in $E_{\text{GABA}}$ result in decreased synaptic inhibition or even paradoxical GABAAergic excitation of VTA GABA neurons in response to GABAAergic activation (Ostroumov et al., 2016; Thomas et al., 2018). Given that benzodiazepines enhance GABAAergic function in VTA GABA neurons (Tan et al., 2010), we hypothesized that acute nicotine exposure would alter the effects of diazepam on VTA GABA neuron activity. To test this, midbrain slices were prepared from rats pretreated with nicotine or saline (15 h prior), and diazepam’s effect on VTA GABA neuron spontaneous firing rate was measured in a cell-attached configuration (Fig. 4A). The basal spontaneous firing rate of GABA neurons was not altered after exposure to the nicotine treatment: 12.9 ± 1.3 Hz in saline-treated versus 10.2 ± 1.2 Hz in nicotine-treated rats (n = 7, n = 8 cells/group, n = 4, n = 5 rats/group, t = −1.584, p = 0.137; Table 1, line k). Bath-application of diazepam (5 μM) on VTA slices from saline-treated control animals decreased GABA neuron firing rate (Fig. 4B, black data), consistent with the enhanced GABAAergic-mediated inhibition of VTA GABA neurons (Tan et al., 2010). In marked contrast, a significant diazepam-induced increase in GABA neuron firing rate was observed following nicotine (Fig. 4B, red trace); group × time, $F_{10,130} = 10.593$, $p = 0.000$ (Table 1, line l). This finding demonstrates that diazepam-dependent enhancement of GABAAergic activity induced GABAAergic excitation of VTA GABA neurons after exposure to nicotine.

To differentiate global diazepam-mediated alterations in VTA GABA neuron firing from local synaptic effects on the patched neurons, we performed brief focal pressure ejection of diazepam onto VTA GABA neurons (Fig. 4D). Upon focal application of diazepam, VTA GABA neurons from control animals showed decreased firing (Fig. 4E,F; black data, 66.0 ± 3.0% of basal firing, n = 17 cells, n = 11 rats). After acute nicotine treatment, local diazepam application produced less GABA-neuron inhibition, and eight out of 17 GABA neurons from nicotine-treated animals showed increased firing to diazepam (Fig. 4E,F, red data; 103 ± 9.9% of basal, n = 17 cells, n = 9 rats, t = 3.592, p = 0.001; Table 1, line m). Taken together, our results show qualitatively similar effects of bath and local diazepam application on VTA GABA neuron firing rate.

Acute nicotine increases diazepam-induced inhibition of DA neurons ex vivo
VTA GABA transmission influences midbrain DA neuron activity and is modulated on exposure to diazepam (Tan et al., 2010). Depolarizing shifts in $E_{\text{GABA}}$ within VTA GABA neurons were previously associated with greater ethanol-induced inhibition of lateral VTA DA neurons (Ostroumov et al., 2016; Thomas et al., 2018). To determine whether acute nicotine exposure altered diazepam-induced GABA release onto DA neurons, we performed whole-cell patch-clamp recordings of lateral VTA DA neurons and measured sIPSCs (Fig. 5A). No significant differences in baseline sIPSC frequency or amplitude were detected between the saline and nicotine groups: 2.2 ± 0.2 Hz in saline-treated versus 2.3 ± 0.4 Hz in nicotine-treated rats, 34.4 ± 4.0 pA in saline-treated versus 34.2 ± 2.8 pA in nicotine-treated rats (t = 0.234, p = 0.817.
for frequency and $t = -0.045$, $p = 0.965$ for amplitude, $n = 14$, $n = 15$ cells, $n = 6$ rats/group, Table 1, lines n, o). In saline-treated control rats, bath-applied diazepam (5 $\mu$m) produced a decrease in sIPSC frequency (Fig. 5A,B): 69.1 $\pm$ 3.8% of basal, black data, $n = 15$ cells, $n = 6$ rats. In contrast, lateral-VTA DA neurons from rats pretreated with nicotine showed a significant diazepam-induced increase in sIPSC frequency compared with control rats (Fig. 5A,B): nicotine-treated, 125.8 $\pm$ 4.4% of basal, red data, $n = 14$ cells, $n = 6$ rats, $t = 9.850$, $p = 0.000$ (Table 1, line p). Importantly, neither group showed alterations in sIPSC amplitude on exposure to diazepam: 103.36 $\pm$ 11.3% in saline-treated rats versus 98.0 $\pm$ 4.9% in nicotine-treated rats ($n = 14$, $n = 15$ cells/group, $n = 6$ rats/group, $t = -0.425$, $p = 0.674$; Table 1, line q). An increase in the frequency, but not the amplitude, of sIPSCs following diazepam suggests enhanced presynaptic GABA release onto the DA neurons. These changes in GABA release in saline-treated and nicotine-treated groups correspond with diazepam-induced inhibition and excitation of VTA GABA neurons, respectively.

To test whether diazepam-induced potentiation of sIPSC frequency involved GABA$_A$R-mediated excitation of VTA GABA neurons, we pharmacologically blocked excitatory GABA$_A$R function. Previous studies reported that depolarizing current through GABA$_A$R is mediated by the outward flow of HCO$_3^-$ ions, which becomes predominant during the loss of the hyperpolarizing Cl$^-$ gradient (Staley et al., 1995; Laviolette et al., 2004; Doyon et al., 2016; Ostroumov et al., 2016). Given that the carbonic anhydrase inhibitor ACTZ blocks the intracellular production of bicarbonate ions and the depolarizing bicarbonate ion efflux, we hypothesized that ACTZ would prevent the diazepam-induced sIPSC frequency increase following nicotine exposure. Bath application of ACTZ (10 $\mu$m) did not change basal sIPSC frequency between control and nicotine groups, nor did it change control responses to diazepam. However, exposure to diazepam in the presence of ACTZ blocked the increase in sIPSC frequency after nicotine (Fig. 5C): 70.2 $\pm$ 7.0% in nicotine-treated animals, and 63.5 $\pm$ 6.3% in saline-treated controls, $n = 7$ cells/group, $n = 3$ rats/group, $t = 0.710$, $p = 0.491$; Table 1, line r), confirming that this increase was due, at least in part, to excitatory GABA$_A$R function.

Next, we hypothesized that excitatory GABA$_A$R function following nicotine exposure derived from the downregulation of KCC2 in VTA GABA neurons. Previous work demonstrated that enhancing Cl$^-$ extrusion with the KCC2 agonist, CLP290, prevents GABAergic excitation of VTA GABA neurons in conditions of dysfunctional KCC2 (Gagnon et al., 2013; Ostroumov et al., 2016; Thomas et al., 2018). To determine whether CLP290 can prevent the enhanced GABA release onto DA neurons observed in the...
nicotine-pretreated animals, we measured sIPSC frequency in slices incubated in CLP290 (>1 h, 10 μM) prior to recordings. The nicotine-mediated potentiation of the sIPSC frequency elicited by diazepam was prevented by CLP290 incubation (Fig. 5D): 65.5 ± 5.9% in nicotine-pretreated animals (red bar with CLP290 treatment) and 74.9 ± 4.3% in saline-pretreated controls (black bar with CLP290 treatment, n = 7, n = 8 cells/group, n = 3, n = 4 rats/group, t = −1.253, p = 0.232; Table 1, line s). Taken together, these results indicate that the effect of acute nicotine pretreatment on diazepam-induced GABA network activity in the VTA was mediated by impaired Cl− homeostasis and altered GABAergic circuit function.

Acute nicotine attenuates diazepam-induced DA activity in vivo

Given that benzodiazepine application typically increases VTA DA neuron firing through disinhibition (O’Brien and White, 1987; Tan et al., 2010), we hypothesized that nicotine-induced depolarization of E\textsubscript{GABA} in VTA GABA neurons would attenuate diazepam-induced DA responses in the lateral VTA. To test this, we conducted in vivo single-unit recordings of lateral VTA DA neurons in anesthetized rats. DA neurons were identified based on their electrophysiological and pharmacological properties (see Materials and Methods; Fig. 1G,H). No significant difference in the mean basal firing rate between groups was observed, 8.0 ± 1.0 Hz after saline versus 8.2 ± 0.9 Hz after nicotine, n = 7 rats/group, t = 0.094, p = 0.926 (Table 1, line t). The spontaneous firing rates of VTA DA neurons were monitored before and after intravenous infusion of diazepam (0.25 mg/kg). The selected dose of diazepam was chosen because it disinhibits VTA DA neurons in rodents and extrapolates to a single dose of 2 mg in humans (O’Brien and White, 1987; Nair and Jacob, 2016). Diazepam administration induced a substantial increase in the spontaneous firing rate of lateral VTA DA neurons in saline-treated controls (Fig. 6A,B, black data): 113.4 ± 3.2% of basal, n = 7 rats. In contrast, DA neurons from nicotine-pretreated animals did not show significant increases in DA firing (Fig. 6A,B, red data): 91.1 ± 4.3% of basal, n = 7 rats, t = −4.11 882, p = 0.001 (Table 1, line u). The VTA recording sites from saline-treated (black) and nicotine-treated (red) rats were similar across experiments (Fig. 6C). Taken together, our data indicate that acute nicotine exposure modified the pharmacological effects of diazepam on VTA circuitry, in particular serving to attenuate diazepam-induced DA responses which correlate with the increased sIPSC frequency observed in the ex vivo experiments.

Acute nicotine increases diazepam intake

Previous work demonstrated that nicotine administration leads to increased consumption of ethanol (Doyon et
Ethanol and diazepam exert their actions on the mesolimbic DA system, in part, through activation of GABAAR on VTA GABA neurons. Therefore, we hypothesized that, like ethanol, diazepam consumption would be increased following acute nicotine exposure. To measure diazepam consumption, we used a 2-h limited access home cage drinking paradigm to elicit substantial short-term diazepam intake in rats, without causing the motor impairment produced by large diazepam doses that could confound interpretation of the results (Fig. 7A; Söderpalm et al., 1991). Stable consumption of saccharin (0.125%, w/v) was first established followed by the introduction of diazepam (0.005 mg/ml) into the drinking solution. This dose of diazepam was selected based on the volume of saccharin solution consumed to correspond with the dose of diazepam given for our in vivo DA neuron recordings. Animals receive an acute injection of either nicotine (0.4 mg/kg) or saline 7 h prior to the first diazepam drinking session. Upon adding diazepam to the drinking solution, nicotine-treated animals substantially increased total fluid intake compared with saline-treated controls (Fig. 7B): group, F(1,17) = 6.12, p = 0.009 (Table 1, line v). Analysis of diazepam consumption according to individual animal weights revealed greater drug intake among nicotine-treated rats compared with controls (Fig. 7C): group, F(1,17) = 5.72, p = 0.029 (Table 1, line w). Mean diazepam intake across the 8-d measurement period was significantly higher for the nicotine-treated group (0.30 ± 0.03 mg/kg) compared with saline-treated rats (0.21 ± 0.02 mg/kg; Fig. 7D, n = 9, n = 10 rats/group, t = 2.391, p = 0.029; Table 1, line x). In separate groups of animals, we measured saccharin consumption in the absence of diazepam and found no difference between nicotine- and saline-treated rats (Fig. 7E).
several days (Doyon et al., 2013; Thomas et al., 2018). In whereas the effect of acute nicotine in adults wanes within three weeks following repeated nicotine in adolescence, tion of VTA GABA signaling persists for more than roadaptations. Previous studies showed that dysregula-
tion between chronic adolescent versus acute adult nicotine exposure in adult animals. Another important differ-
ence can arise in response to a single nicotine exposure, diazepam-induced inhibition of VTA GABA neurons was diminished and shifted toward excitation. This transition in GABAAR function arises from im-
paired Cl\(^{-}\) extrusion and downregulation of the K\(^{+}\), Cl\(^{-}\) transporter KCC2 (Staley et al., 1995; Ostromov et al., 2016). Upon diazepam-induced potentiation of GABAAR activity, diminished function of KCC2 leads to the accumu-
lation of Cl\(^{-}\) inside the neuron and subsequent collapse of the Cl\(^{-}\) gradient (Fig. 2D,E), which is necessary for the hyper-
peralizing GABAAR function (Staley et al., 1995; Hewitt et al., 2009). An activity-dependent decrease in the hyper-
peralizing Cl\(^{-}\) gradient decreases GABAergic inhibition and unmarks an outward flux of HCO\(_{3}^{-}\) ions through GABAARs, resulting in neuronal depolarization/excitation (Bormann et al., 1987; Kaila, 1994; Hewitt et al., 2009; Doyon et al., 2016). Consistent with this model, enhancing Cl\(^{-}\) extrusion with CLP290 or attenuating HCO\(_{3}^{-}\} efflux with ACTZ prevented diazepam-induced excitation of VTA GABA circuitry (Fig. 5B–D).

Downstream of KCC2 and VTA GABA neuron alter-
ations, we observed diazepam-induced inhibition of lateral VTA DA neurons and increased diazepam intake in nicotine-treated animals. We speculate that adaptations in the inhibitory input onto VTA DA neurons arise from local GABA neurons, but other afferent projections may play a role as well. The correlation between attenuated diaz-
epam-induced DA responses and increased addictive be-
haviors is consistent across different species and multiple drugs of abuse, including alcohol, nicotine, cocaine and marijuana (Martinez et al., 2007; Lack et al., 2008; Audrain-McGovern et al., 2012; Wang et al., 2012; Doyon et al., 2013; Volkow et al., 2014; Twining et al., 2015; Ostromov et al., 2016; Büchel et al., 2017; Thomas et al., 2018). Clinical and preclinical studies associate blunted DA signaling with decreased reward sensitivity and perpetuation of drug use as a means to overcome the attenu-
ated subjective effects (Martinez et al., 2007; Volkow et al., 2010, 2014; Taylor et al., 2015, 2016; Twining et al., 2015). In parallel, GABA-mediated persistent decreases in DA neuron activity effectively increase phasic DA re-
 sponses to salient, drug-related stimuli that may drive ad-
dictive-like behaviors (Wanat et al., 2009; Tolu et al., 2013; Morozova et al., 2016; Schindler et al., 2016; Kruse et al., 2017). In this way, phasic DA signals stand out from

Discussion

In the present work, we demonstrated in rats that exposure to nicotine modifies the pharmacological action of diazepam on VTA circuitry and is associated with increased diazepam intake. In VTA GABA neurons, acute nicotine exposure caused a depolarizing shift in the GABA\(_{A}\)R reversal potential (E\(_{GABA}\)), which corresponded with diminished Cl\(^{-}\) extrusion capacity and decreased KCC2 expression. These nicotine-induced alterations in Cl\(^{-}\) homeostasis shifted the effect of diazepam on VTA GABA neurons from inhibition toward excitation and were associated with enhanced GABA\(_{A}\)-R inhibition of DA neurons in the lateral VTA on diazepam exposure. Critically, enhancing KCC2-mediated Cl\(^{-}\) extrusion in nicotine-treated animals prevented alterations in diazepam-induced VTA GABA transmission (Fig. 5D) and reduced diazepam consumption to control levels (Fig. 7G,H).

A depolarizing shift in E\(_{GABA}\) results in decreased syn-
aptic inhibition or even paradoxical GABA\(_{A}\)-mediated excitation of VTA GABA neurons. Although previous work reports depolarizing shifts in GABA\(_{A}\)R signaling within the VTA following repeated adolescent nicotine administration (Thomas et al., 2018), the current results demonstrate that these adaptations can arise in response to a single nicotine exposure in adult animals. Another important differ-
ence between chronic adolescent versus acute adult nicotine exposure is the duration of nicotine-induced neuro-
adaptations. Previous studies showed that dysregula-
tion of VTA GABA signaling persists for more than three weeks following repeated nicotine in adolescence, whereas the effect of acute nicotine in adults wanes within several days (Doyon et al., 2013; Thomas et al., 2018). In addition to nicotine, treatments that shift GABA\(_{A}\)R signal-
ing toward excitation in VTA GABA neurons include ab-
rupt withdrawal from chronic morphine or ethanol, as well as aversive or pain states (Taylor et al., 2015, 2016; Ostromov et al., 2016; Nelson et al., 2018). Together with this literature, our findings indicate that experience-
dependent depolarizing shifts in GABA\(_{A}\)R signaling repre-
sent a common, yet remarkably understudied, form of inhibitor synaptic plasticity in the VTA.

Plasticity of inhibitory transmission on VTA GABA neu-
rons can modify the pharmacological action of addictive
drugs that target GABA\(_{A}\)R (Vashchinkina et al., 2014). In agreement with previous studies (O'Brien and White, 1987; Tan et al., 2010), our findings show that positive modulation of GABA\(_{A}\)R signaling by diazepam attenuates VTA GABA neuron activity in drug naïve animals. However, after nicotine exposure, diazepam-induced inhibition of VTA GABA neurons was diminished and shifted toward excitation. This transition in GABA\(_{A}\)R function arises from im-
paired Cl\(^{-}\) extrusion and downregulation of the K\(^{+}\), Cl\(^{-}\) transporter KCC2 (Staley et al., 1995; Ostromov et al., 2016). Upon diazepam-induced potentiation of GABA\(_{A}\)R activity, diminished function of KCC2 leads to the accumu-
lation of Cl\(^{-}\) inside the neuron and subsequent collapse of the Cl\(^{-}\) gradient (Fig. 2D,E), which is necessary for the hyper-
peralizing GABA\(_{A}\)R function (Staley et al., 1995; Hewitt et al., 2009). An activity-dependent decrease in the hyper-
peralizing Cl\(^{-}\) gradient decreases GABAergic inhibition and unmarks an outward flux of HCO\(_{3}^{-}\} ions through GABAARs, resulting in neuronal depolarization/excitation (Bormann et al., 1987; Kaila, 1994; Hewitt et al., 2009; Doyon et al., 2016). Consistent with this model, enhancing Cl\(^{-}\) extrusion with CLP290 or attenuating HCO\(_{3}^{-}\} efflux with ACTZ prevented diazepam-induced excitation of VTA GABA circuitry (Fig. 5B–D).
the background DA, producing an increased signal-to-noise for salient events. Our electrophysiological data were collected in slices or in anesthetized animals and correspond to pharmacological responses to diazepam in the absence of cues. Therefore, future work should examine how exposure to nicotine alters phasic and tonic DA responding in vivo during addictive behaviors.

Recent epidemiological studies report a steep rise in benzodiazepine misuse and overdose mortality, occurring most commonly in poly drug users (Dunbar et al., 1988; Woods et al., 1992; Griffiths and Weerts, 1997; Lekka et al., 1997; Neutel, 2005; Licata and Rowlett, 2008; Bachhuber et al., 2016; Lembke et al., 2018; Maust et al., 2019). We showed that nicotine pretreatment increases diazepam intake for several days. The prolonged behavioral effect of a single nicotine exposure suggests that KCC2 downregulation serves as a form of metaplasticity, facilitating downstream diazepam-induced neuroadaptations that maintain elevated consumption (Creed and Lüscher, 2013; Cui et al., 2013; Ostroumov and Dani, 2018). An important parameter in our experimental design is that the nicotine exposure was well separated (7–15 h) from diazepam exposure, which allowed us to examine the lasting neural circuit consequences of the treatment not the proximal effect of nicotine itself. Although dysregulated VTA GABA transmission was observed following repeated nicotine administration (Fig. 3; Thomas et al., 2018), future work should explore the impact of chronic nicotine-induced KCC2 downregulation on nicotine-benzodiazepine coabuse.

Following nicotine administration, elevated diazepam intake was associated with midbrain KCC2 dysfunction and could be prevented by the KCC2 agonist, CLP290. These results suggest that Cl− extrusion enhancers may serve as a therapeutic strategy to mitigate excessive diazepam consumption in smoking populations (Dunbar et al., 1988; Lekka et al., 1997; Neutel, 2005). Moreover, KCC2 hypofunction and compromised GABAergic inhibition have been observed following other risk factors for benzodiazepine abuse, including opiates and alcohol (Laviolette et al., 2004; Taylor et al., 2016; Nelson et al., 2018), suggesting that alterations in midbrain KCC2 are a neurobiological mechanism contributing to the vulnerability to benzodiazepine abuse. Taken together, our results reveal that acute nicotine exposure induces long-lasting alterations in mesolimbic responses to benzodiazepines and promotes diazepam consumption in rats. While it is known that nicotine use increases the risk for abuse of other drugs, our data demonstrate that this association extends to benzodiazepines. Moreover, we provide novel insight into the circuit and molecular adaptations giving rise to heightened diazepam consumption after nicotine exposure.

References

Audrain-McGovern J, Rodriguez D, Leventhal AM, Cuevas J, Rodgers K, Sass J (2012) Where is the pleasure in that? Low hedonic capacity predicts smoking onset and escalation. Nicotine Tob Res 14:1187–1196.

Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL (2016) Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health 106:686–688.

Bormann J, Hamill OP, Sakmann B (1987) Mechanism of anion permeation through channels gated by glycine and gamma-aminobutyric acid in mouse cultured spinal neurones. J Physiol 385:243–286.

Boscarino JA, Rukstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, Stewart WF (2010) Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:1776–1782.

Büchel C, Peters J, Banaschewski T, Bokde AL, Bromberg U, Conrod PJ, Flor H, Papadopoulos D, Garavan H, Gowland P, Heinz A, Walter H, Ittermann B, Mann K, Martinot JL, Pailliére-Martinot ML, Nees F, Paus T, Pausova Z, Poustka L, Rietschel M, et al. (2017) Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents. Nat Commun 8:14140.

Buczynski MW, Herman MA, Hsu KL, Natividad A, Irimia C, Polis YI, Pugh H, Chang JW, Niphakis MJ, Cravatt BF, Roberto M, Parsons LH (2016) Diacylglycerol lipase disinhibits VTA dopamine neurons during chronic nicotine exposure. Proc Natl Acad Sci USA 113:1086–1091.

Chen BT, Bowers MS, Martin M, Hopf FW, Guillory AM, Carelli RM, Chou JK, Bonci A (2008) Cocaine but not natural reward self-administration nor passive cocaine infusion produces persistent LTP in the VTA. Neuron 59:288–297.

Creed MC, Lüscher C (2013) Drug-evoked synaptic plasticity: beyond metaplasticity. Curr Opin Neurobiol 23:553–558.

Cui C, Norohna A, Morikawa H, Alvarez VA, Stuber GD, Szumlinski KK, Kash TL, Roberto M, Wilcox MV (2013) New insights on neurobiological mechanisms underlying alcohol addiction. Neuropharmacology 67:223–232.

Doyon WM, Dong Y, Ostromoukhov A, Thomas AM, Zhang TA, Dani JA (2013) Nicotine decreases ethanol-induced dopamine signaling and increases self-administration via stress hormones. Neuron 79:530–540.

Doyon N, Vinay L, Prescott SA, De Koninck Y (2016) Chloride regulation: a dynamic equilibrium crucial for synaptic inhibition. Neuron 89:1157–1172.

Dunbar GC, Morgan DD, Perera KM (1988) The concurrent use of alcohol, cigarettes and caffeine in British benzodiazepine users as measured by a general population survey. Br J Addict 83:689–694.

Ferrini F, Lorenzo LE, Godin AG, Quang ML, De Koninck Y (2017) Enhancing KCC2 function counteracts morphine-induced hyperalgesia. Sci Rep 7:3870.

Gagnon M, Bergeron MJ, Lavergu L, Castonguay A, Tripathy S, Bonin RP, Perez-Sanchez J, Boudreau D, Wang B, Dumas L, Valade I, Bachand K, Jacob-Wagner M, Tardif C, Kianicka I, Isenring P, Attardo G, Cours JA, De Koninck Y (2013) Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat Med 19:1524–1528.

Griffiths RR, Weerts EM (1997) Benzodiazepine self-administration in humans and laboratory animals—implications for problems of long-term use and abuse. Psychopharmacology (Berl) 134:1–37.

Harrison EL, McKee SA (2011) Non-daily smoking predicts hazardous drinking and alcohol use disorders in young adults in a longitudinal U.S. sample. Drug Alcohol Depend 118:78–82.

Hewitt SA, Wamsteeker JI, Kurz EU, Bains JS (2009) Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis. Nat Neurosci 12:438–443.

Huizing AC, Levai L, Torkolay E, Korhonen T, Dick DM, Pulkinnen L, Rosé RJ, Kajander J (2010) Tobacco, cannabis, and other illicit drug use among Finnish adolescent twins: causal relationship or correlated liabilities? J Stud Alcohol Drugs 71:5–14.

Irving EE, Cheeta S, Lovelock C, File SE (2001) Tolerance to midazolam’s anxiolytic effects after short-term nicotine treatment. Neuropharmacology 40:710–716.
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F, Baler R (2010) Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain’s control circuit. Bioessays 32:748–755.

Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, Logan J, Jayne M, Wong C, Tomasi D (2014) Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci USA 111:E3149–E3156.

Wanat MJ, Willuhn I, Clark JJ, Phillips PE (2009) Phasic dopamine release in appetitive behaviors and drug addiction. Curr Drug Abuse Rev 2:195–213.

Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, Wong CT, Hoffman W, Jayne M, Alia-Klein N, Thanos P, Fowler JS (2012) Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17:918–925.

White JM (1989) Behavioral interactions between nicotine and diazepam. Pharmacol Biochem Behav 32:479–482.

Woods JH, Katz JL, Winger G (1992) Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44:151–347.

Zhang TA, Placzek AN, Dani JA (2010) In vitro identification and electrophysiological characterization of dopamine neurons in the ventral tegmental area. Neuropharmacology 59:431–436.